Cerevel Therapeutics Initiates Phase 3 Program Testing Tavapadon for Improved Motor Function

Cerevel Therapeutics Initiates Phase 3 Program Testing Tavapadon for Improved Motor Function
Cerevel Therapeutics announced its launch of a series of Phase 3 clinical trials to evaluate its investigational therapy tavapadon, designed to improve motor function in people with Parkinson’s disease. The company will conduct three 27-week trials to evaluate tavapadon’s efficacy, safety, and tolerability in fixed doses — TEMPO-1 (NCT04201093) — and flexible doses — TEMPO-2 (NCT04223193) and TEMPO-3 (not yet ... read more
Source: Parkinson’s News TodayPublished on 2020-01-16By Forest Ray